# Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis

#### **Additional File 2**

Máté Rottler<sup>\*1,4,5</sup>, Klementina Ocskay<sup>\*1,2</sup>, Zoltán Sipos<sup>1</sup>, Anikó Görbe<sup>1</sup>, Marcell Virág<sup>1,4,5</sup>, Péter Hegyi<sup>1,2,3</sup>, Tihamér Molnár<sup>6</sup>, Bálint Erőss<sup>1,2,3</sup>, Tamás Leiner<sup>1,7</sup>, Zsolt Molnár<sup>2,3,5,8,9</sup>

<sup>1</sup> Institute for Translational Medicine, Szentágothai Research Centre, Medical School, University of Pécs, Pécs, Hungary

<sup>2</sup> Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

<sup>3</sup> Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary

<sup>4</sup> Department of Anaesthesiology and Intensive Therapy, Szent György University Teaching Hospital of Fejér County, 8000 Székesfehérvár, Hungary

<sup>5</sup> Doctoral School of Clinical Medicine, University of Szeged, 6720 Szeged, Hungary

<sup>6</sup> Department of Anaesthesiology and Intensive Therapy, University of Pécs, 7624 Pécs

<sup>7</sup> Anaesthetic Department, Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon PE29 6NT, UK

<sup>8</sup> Department of Anaesthesiology and Intensive Therapy, Poznan University of Medical Sciences, 61-701 Poznan, Poland

<sup>9</sup>Department of Anaesthesiology and Intensive Therapy, Semmelweis University, 1082, Budapest, Hungary

\* Authors contributed equally

Correspondence to: Zsolt Molnár; zsoltmolna@gmail.com; Tel: +36-30-302-6668

## Table of contents

Risk of bias assessment	4
Risk of bias assessment protocol	4
Figure S1 — In-hospital mortality	5
Figure S2 — 30-day mortality	6
Figure S3 — Average frailty comparing deceased and discharged COVID-19 patients	7
Figure S4 — Average frailty comparing COVID-19 patients who survived for 30-days vs wh survive	o did not 8
Figure S5 — ICU admission	9
Figure S6 — Length of hospital stay	10
Mortality in patients with CFS 1–3 vs 4–9	11
Figure S7 – Forest plot for mortality grouped by follow-up	11
Figure S8 – Forest plot grouped by age restriction	12
Figure S9 – Leave-one-out analysis	13
Figure S10 – Funnel plot	14
Mortality in patients with CFS 1–4 vs 5–9	15
Figure S11 — Forest plot for mortality grouped by follow-up	15
Figure S12 — Forest plot grouped by age restriction	16
Figure S13 – Leave-one-out analysis	17
Figure S14 – Funnel plot	18
Mortality in patients with CFS 1–5 vs 6–9	19
Figure S15 – Forest plot, studies grouped by country	19
Figure S16 — Forest plot for mortality grouped by follow-up	20
Figure S17 — Forest plot grouped by age restriction	21
Figure S18 — Leave-one-out analysis	22
Figure S19 – Funnel plot	23
Weighted Mean Difference of CFS	24
Figure S20 – Forest plot, studies grouped by country	24
Figure S21 – Forest plot for mortality grouped by follow-up	25
Figure S22 — Leave-one-out analysis	26
Figure S23 – Funnel plot	27
Mortality in patients with MPI 1 vs 2+3	28
Figure S24 – Forest plot	28
ICU admission in patients with CFS 1–3 vs 4–9	29

Figure S25 – Leave-one-out analysis	29
Figure S26 – Funnel plot	30
ICU admission in patients with CFS 1–4 vs 5–9	31
Figure S27 – Forest plot	31
Figure S28 – Leave-one-out analysis	32
Figure S29 – Funnel plot	33
Length of hospital stay	34
Summary of reported results	34
References	35

### Risk of bias assessment

#### Risk of bias assessment protocol

Following the recommendations of the Cochrane Collaboration, the Quality in Prognosis Studies (QUIPS) tool was used by MR and TL independently [1]. Disagreements were resolved by ZM. In the study participation domain gender, age, ethnicity and comorbidities were taken into account. Study attrition was not judged for retrospective studies. In the prognostic factor measurement domain, the specification of the frailty assessor, information about their training and missing data on frailty were taken into account. Less than 10% missing data was considered low risk, 10–20% some concerns and more than 20% resulted in high risk for the whole domain. Outcome measurement and statistical analysis domains carried low risk in most cases because mortality is a hard outcome and we mostly used raw data. In case of ICU admission, a detailed protocol for ICU admission was needed. In the study confounding domain, studies reporting baseline information for the frailty groups separately were judged low risk if no clinically significant differences were seen, some concerns if some differences were seen and high risk if no data was reported. The overall risk of bias was calculated using the suggestions of Grooten et al. [2].

### Figure S1 — In-hospital mortality

A	n.a. Not applicable Low risk Moderate risk High risk	Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
	Andrés-Esteban, E. M. et al. (2021)	-	n.a.	+	+	+	+	-	Yes
	Covino, M. et al. (2021)	+		+	+	+	+	+	Yes
	Aw, D. et al. (2020)	+	n.a.	+	+	+	+	+	Yes
	Blomaard, L. C. et al. (2021)	+	n.a.	-	+	?	+	-	Yes
	Burns GP et al. (2020)	?	n.a.	+	+	-	+	-	Yes
	Chinnadurai, R. et al. (2020)	+	n.a.	+	?	-	+	-	Yes
	Bavaro, D. F. et al. (2021)	+	n.a.	?	+	+	+	+	Yes
	De Smet, R. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
	Fagard K. et al. (2021)	?	n.a.	+	+	-	+	-	Yes
	Hewitt, J. et al. (2020)	+	+	+	+	-	+	-	Yes
	Lozano-Montoya, I. et al. (2021)	-	-	-	+	-	+	-	Yes
CFS	Marengoni, A. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
CFS	Mendes A. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
	Moloney, E. et al. (2020)	+	n.a.	+	+	+	+	+	Yes
	Noble, J. H. Et al. (2021)	-		-	-	-	-	-	Yes
	Piers, R. et al. (2021)	-	n.a.	+	+	-	+	-	Yes
	Ponsford, M. J. et al. (2021)	+		-	-	-	+	-	Yes
	Ramos-Rincon, J. M. Et al (2021)	+	n.a.	+	+	+	+	+	Yes
	Sablerolles, R. S. G. et al. (2021)	+	n.a.	+	+	+	+	+	Yes
	Tehrani, S. et al. (2021)	+	n.a.	+	+	-	+	-	Yes
	Thiam, C. N. et al. (2021)	-		-	-	-	+	-	Yes
	Osuafor C.N. et al. (2021)	+	n.a.	+	+	+	+	+	Yes
	Welch, C. et al. (2021)	-	-	-	+	-	+	-	Yes
	Wolfisberg, S. et al. (2021)	+	n.a.	?	+	-	+	-	Yes
	Kundi, H. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
HFRS	Navaratnam, A. V. et al. (2021)	+	n.a.	+	+	-	+	-	Yes
	Ramos-Rincon, J. M. et al. (2021)	+	n.a.	+	+	+	+	+	Yes
	Maki, Y. et al. (2021)	-	n.a.	-	-	-	-	-	Yes
MPI	Pilotto, A. et al. (2021)	-	-	+	+	+	+	-	Yes
	Verholt, A. B. et al. (2021)	-	n.a.	?	+	?	+	-	Yes
mFI	Fumigalli, C. et al. (2021)	+	n.a.	?	+	-	+	-	No
_	Study participation Study attrition nostic factor measurement Outcome measurement Study confounding								
Sta	atistical analysis reporting			-					
	Overall risk of bias								

#### Figure S1 Risk of bias assessment on study level [A] and across studies [B] for studies reporting inhospital mortality

For details please see the protocol for risk of bias assessment above.

#### Figure S2 — 30-day mortality

A	n.a. Not applicable Low risk Moderate risk High risk	Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
	Aliberti, M. J. R. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
	Apea, V. J. et al. (2021)	+	n.a.	-	+	-	+	-	Yes
	Bielza, R. et al. (2021)	+	n.a.	?	+	-	+	-	Yes
	Davis, P. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
CFS	Dres, M. et al. (2021)	-	-	-	+	-	+	-	Yes
	Gilis, M. et al. (2020)	+	+	+	+	+	+	+	Yes
	Jung, C. et al. (2021)	+	+	+	+	-	+	-	Yes
	Maguire, D. et al. (2021)	+	n.a.	-	+	-	+	-	No
	Owen, R. K. et al. (2020)	?	n.a.	-	+	-	+	-	Yes
HFRS	Apea, V. J. et al. (2021)	+	n.a.	+	+	-	+	-	Yes
mFI	Kurtz, P. et al. (2021)	+	-	-	+	-	+	-	No




Figure S2 Risk of bias assessment on study level [A] and across studies [B] for studies reporting 30day mortality

For details please see the protocol for risk of bias assessment above.

A	n.a. Not applicable	Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
	Andrés-Esteban, E. M. et al. (2021)	-	n.a.	+	+	+	+	-	Yes
	Brill, S.E. et al. (2020)	+	n.a.	-	+	-	+	-	No
	Burns, G. P. et al. (2020)	?	n.a.	+	+	-	+	-	Yes
	Cecchini, S. et al. (2021)	+	n.a.	-	+	-	+	-	No
	Cuvelier, C. et al. (2021)	-	n.a.	-	-	-	-	-	No
	De Smet, R. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
	Fagard, K. et al. (2021)	?	n.a.	+	+	-	+	-	Yes
CFS	Hoek, R.A.S. et al. (2020)	?	n.a.	?	?	-	?	-	No
	Koduri, G. et. al. (2021)	+	n.a.	-	-	-	+	-	No
	Knights, H. et al. (2020)	+	n.a.	?	+	-	+	-	Yes
	Kundi, H. et al. (2020)	+	n.a.	+	+	-	+	-	No
	Mendes, A. et al. (2020)	+	n.a.	+	+	-	+	-	Yes
	Straw, S. et al. (2021)	+	n.a.	+	+	-	+	-	Yes
	van Steenkiste, J. et al. (2021)	+	n.a.	-	+	-	+	-	No
	Wolfisberg, S. et al. (2021)	+	n.a.	?	+	-	+	-	Yes

#### Figure S3 — Average frailty comparing deceased and discharged COVID-19 patients




Figure S3 Risk of bias assessment on study level [A] and across studies [B] for studies reporting average frailty comparing discharged and deceased COVID-19 patients For details please see the protocol for risk of bias assessment above.

# Figure S4 — Average frailty comparing COVID-19 patients who survived for 30-days vs who did not survive

A	n.a. Not applicable				Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
	Baker, K. F. et al. (2021)				+	n.a.	-	+	-	+	-	Yes
	Bielza, R. et al. (2021)				+	n.a.	?	+	-	+	-	Yes
CFS	Bradley, P. et al. (2020)				?	n.a.	+	+	-	+	-	Yes
	Fallon, A. et al. (2021)				-	n.a.	-	-	-	-	-	No
	Moledina, S. M. et al. (202	20)			+	n.a.	?	+	-	+	-	Yes
-	Study participation Study attrition nostic factor measurement Outcome measurement Study confounding atistical analysis reporting Overall risk of bias		20%	40%			50%		80%			00%

Figure S4 Risk of bias assessment on study level [A] and across studies [B] for studies reporting average frailty comparing COVID-19 patients who survived for 30 days and who did not For details please see the protocol for risk of bias assessment above.

### Figure S5 - ICU admission


n.a. Not applicable Low risk Moderate risk High risk		Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
Andrés-Esteban, E. M. et al	(2021)	-	n.a.	+	-	+	+	-	Yes
Aw, D. et al. (2020)		+	n.a.	+	-	+	+	-	Yes
Blomaard, L. C. et al. (2021	)	+	n.a.	-	-	?	+	-	Yes
Gilis, M. et al. (2020)		+	+	+	-	+	+	-	Yes
Marengoni, A. et al. (2020)		+	n.a.	+	+	-	+	-	No
Osuafor C.N. et al. (2021)		+	n.a.	+	-	+	+	-	Yes
Owen, R. K. et al. (2020)		?	n.a.	-	+	-	+	-	Yes
Piers, R. et al. (2021)		-	n.a.	+	-	-	+	-	Yes
Ramos-Rincon, J. M. et al. (	/	+	n.a.	+	+	+	+	+	Yes
Sablerolles, R. S. G. et al. (2	021)	+	n.a.	+	+	-	+	-	Yes
Wolfisberg, S. et al. (2021)		+	n.a.	?	+	-	+	-	Yes
Study participation Study attrition ostic factor measurement Outcome measurement Study confounding tistical analysis reporting Overall risk of bias									
Outc S tistical	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	Actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias	actor measurement come measurement Study confounding analysis reporting Overall risk of bias

Figure S5 Risk of bias assessment on study level [A] and across studies [B] reporting intensive care admission

For details, please see the protocol for risk of bias assessment above.

#### Figure S6 — Length of hospital stay

A	n.a. Not applicable Low risk Moderate risk High risk	Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis reporting	Overall risk of bias	Included in meta- analyses
	Andrés-Esteban, E. M. et al. (2021)	-	n.a.	+	+	+	+	ł	No
	Bavaro, D. F. et al. (2021)	+	n.a.	?	-	+	+	ł	No
	Blomaard, L. C. et al. (2021)	+	n.a.	-	+	?	+	ł	No
CFS	Hewitt, J. et al. (2020)	+	+	+	+	-	+	-	No
	Kundi, H. et al. (2020)	+	n.a.	+	+	-	+	-	No
	Osuafor C.N. et al. (2021)	+	n.a.	?	+	+	+	+	No
	Ramos-Rincon, J. M. et al. (2021)	+	n.a.	+	+	+	+	+	No
HFRS	Ramos-Rincon, J. M. et al. (2021)	+	n.a.	+	+	+	+	+	No



**Figure S6 Risk of bias assessment on study level [A] and across studies [B] reporting length of stay** For details, please see the protocol for risk of bias assessment above.

## Mortality in patients with CFS 1–3 vs 4–9

Figure S7 – Forest plot for mortality grouped by follow-up

Studies		OR (95% CI)	Events, Patients with frailty	Events, Patients without frailty	% Weight
In-hospital mortality					
Piers, R. et al. (2021)	•	1.50 (0.94, 2.41)	218/610	27/100	6.61
Aw, D. et al. (2020)		2.08 (1.29, 3.35)	245/567	26/97	6.54
Andrés-Esteban, E. M. et al. (2021)		2.15 (1.25, 3.69)	42/78	62/176	5.91
Hewitt, J. et al. (2020)	-	3.06 (2.34, 3.99)	338/984	84/575	8.86
Wolfisberg, S. et al. (2021)		3.38 (2.06, 5.55)	66/235	26/251	6.36
Sablerolles, R. S. G. et al. (2021)	-	3.68 (2.96, 4.57)	314/1057	142/1377	9.35
Ponsford, M. J. et al. (2021)	-	4.24 (3.27, 5.49)	380/770	100/535	8.94
Welch, C. et al. (2021)	-	4.27 (3.67, 4.97)	1117/3012	251/2069	9.93
Tehrani, S. et al. (2021)		5.35 (1.94, 14.78)	47/105	5/38	2.81
Thiam, C. N. et al. (2021)		7.50 (0.73, 76.77)	5/13	1/13	0.68
Bavaro, D. F. et al. (2021)	•	10.83 (3.23, 36.27)	53/146	3/60	2.15
Covino, M. et al. (2021)		21.95 (5.32, 90.59)	285/668	2/61	1.66
Subtotal (I-squared = 72.6%, p = 0.000)	$\diamond$	3.39 (2.70, 4.26)	3110/8245	729/5352	69.81
30-day mortality					
Aliberti, M. J. R. et al. (2020)	-	2.21 (1.82, 2.68)	369/788	297/1042	9.58
Jung, C. et al. (2021)	-	2.30 (1.83, 2.90)	256/464	299/858	9.23
Dres, M. et al. (2021)	-	3.14 (2.35, 4.19)	162/259	287/826	8.61
Davis, P. et al. (2020)		3.17 (1.14, 8.82)	90/198	5/24	2.77
Subtotal (I-squared = 31.5%, p = 0.223)	$\diamond$	2.46 (2.07, 2.93)	877/1709	888/2750	30.19
Overall (I-squared = 78.6%, p = 0.000)	$\diamond$	3.12 (2.56, 3.81)	3987/9954	1617/8102	100.00
NOTE: Weights are from random effects analysis					
.1 1	3	I 100			
Lower chance in frail patien					

#### Figure S7 30-day and in-hospital mortality in patients with frailty indicated by CFS

Frail patients (CFS 4–9) have significantly higher odds of in-hospital (OR: 3.39; CI: 2.70–4.26) and 30day mortality (OR: 2.46; CI: 2.07–2.93), the overall odds ratio being 3.12 (CI: 2.56–3.81). Note that heterogeneity was not significant for 30-day mortality, but significant for in-hospital mortality and in overall. OR: odds ratio; CI: confidence interval. P>0.1 was considered significant.


#### Figure S8 – Forest plot grouped by age restriction

		Events, Patients	Events, Patients	%
Studios	00 (05% CI)			
Studies	OR (95% CI)	with frailty	without frailty	vveign
Older than 65 years				
Piers, R. et al. (2021)	1.50 (0.94, 2.41)	218/610	27/100	6.61
Aw, D. et al. (2020)	2.08 (1.29, 3.35)	245/567	26/97	6.54
Jung, C. et al. (2021)	2.30 (1.83, 2.90)	256/464	299/858	9.23
Dres, M. et al. (2021)	3.14 (2.35, 4.19)	162/259	287/826	8.61
Tehrani, S. et al. (2021)	5.35 (1.94, 14.78)	47/105	5/38	2.81
Bavaro, D. F. et al. (2021)	• 10.83 (3.23, 36.27)	53/146	3/60	2.15
Covino, M. et al. (2021)	21.95 (5.32, 90.59)	285/668	2/61	1.66
Subtotal (I-squared = 76.4%, p = 0.000)	3.09 (2.08, 4.60)	1266/2819	649/2040	37.61
No age restriction				
Andrés-Esteban, E. M. et al. (2021)	2.15 (1.25, 3.69)	42/78	62/176	5.91
Aliberti, M. J. R. et al. (2020)	2.21 (1.82, 2.68)	369/788	297/1042	9.58
Hewitt, J. et al. (2020)	3.06 (2.34, 3.99)	338/984	84/575	8.86
Davis, P. et al. (2020)	3.17 (1.14, 8.82)	90/198	5/24	2.77
Wolfisberg, S. et al. (2021)	3.38 (2.06, 5.55)	66/235	26/251	6.36
Sablerolles, R. S. G. et al. (2021)	3.68 (2.96, 4.57)	314/1057	142/1377	9.35
Ponsford, M. J. et al. (2021)	4.24 (3.27, 5.49)	380/770	100/535	8.94
Welch, C. et al. (2021)	4.27 (3.67, 4.97)	1117/3012	251/2069	9.93
Thiam, C. N. et al. (2021)	7.50 (0.73, 76.77)	5/13	1/13	0.68
Subtotal (I-squared = 77.0%, p = 0.000)	3.27 (2.63, 4.08)	2721/7135	968/6062	62.39
Overall (I-squared = 78.6%, p = 0.000)	3.12 (2.56, 3.81)	3987/9954	1617/8102	100.00
NOTE: Weights are from random effects analysis				
.1 1 3	100			

## Figure S8 Mortality in frail patients indicated by CFS (1–3 vs 4–9), with studies grouped by age restriction

Studies only enrolling patients older than 65 years of age have an overall odds ratio of 3.09 (CI: 2.08– 4.60) for mortality in frail patients (CFS 5–9) while studies without age restriction have an overall OR of 3.27 (CI: 2.63–4.08). Note that heterogeneity was significant in both subgroups and for the overall results as well. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.

#### Figure S9 – Leave-one-out analysis



## Figure S9 Leave-one-out sensitivity analysis for studies reporting mortality in patients with CFS 1–3 vs CFS 4–9

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

### Figure S10 – Funnel plot




Figure S10 Funnel plot for mortality in patients with CFS 1–3 vs 4–9

Based on the visual inspection of the funnel plot and the result of the Eggers' test (p=0.858) no small study effect was identified.

### Mortality in patients with CFS 1-4 vs 5-9


#### Figure S11 — Forest plot for mortality grouped by follow-up

Studies		Events, CFS 5-9	Events, CFS 1-4	% Weight
30-day mortality				
Owen, R. K. et al. (2020)	0.85 (0.49, 1.47)	47/110	45/96	4.78
Apea, V. J. et al. (2021)	1.70 (1.28, 2.26)	189/431	126/400	6.42
Gilis, M. et al. (2020)	1.75 (0.91, 3.39)	38/109	18/77	4.16
Davis, P. et al. (2020)	1.76 (0.93, 3.34)	77/167	18/55	4.27
Aliberti, M. J. R. et al. (2020)	2.40 (1.94, 2.97)	255/494	411/1336	6.79
Jung, C. et al. (2021)		164/275	391/1047	6.49
Subtotal (I-squared = 68.9%, p = 0.007)	1.84 (1.40, 2.41)	770/1586	1009/3011	32.91
In-hospital mortality				
Moloney, E. et al. (2020)	0.93 (0.29, 2.96)	10/44	6/25	2.19
Piers, R. et al. (2021)	1.18 (0.83, 1.69)	186/524	59/186	5.99
Burns GP et al. (2020)	1.35 (0.29, 6.18)	9/17	5/11	1.45
Aw, D. et al. (2020)	2.01 (1.40, 2.87)	214/470	57/194	5.98
Andrés-Esteban, E. M. et. al. (2021)	2.44 (1.26, 4.74)	26/44	78/210	4.14
Hewitt, J. et al. (2020)	2.56 (2.02, 3.24)	286/799	136/760	6.68
Lozano-Montoya, I. et al. (2021)	2.60 (1.44, 4.68)	92/216	18/81	4.56
Osuafor C.N. et al. (2021)	2.70 (1.40, 5.22)	59/142	15/72	4.16
Welch, C. et al. (2021)	3.28 (2.88, 3.74)	943/2441	425/2640	7.11
Ponsford, M. J. et al (2021)	3.49 (2.76, 4.43)	317/612	163/693	6.67
Noble, J. H. Et al. (2021)	3.51 (1.03, 11.91)	9/13	59/151	2.03
Tehrani, S. et al. (2021)	3.99 (1.98, 8.05)	43/71	20/72	3.93
Mendes A. et al. (2020)	5.61 (2.12, 14.79)	71/185	5/50	2.77
De Smet, R. et al. (2020)	♦ 6.26 (0.77, 50.74)	18/64	1/17	0.85
Chinnadurai, R. et al. (2020)	8.71 (4.56, 16.64)	69/110	17/105	4.23
Ramos-Rincon, J. M. Et al (2021)	13.25 (6.50, 26.98)	29/54	19/236	3.89
Fagard K. et al. (2021)	● 26.01 (1.51, 449.10)	14/62	0/43	0.48
Subtotal (I-squared = 78.3%, p = 0.000)	3.10 (2.40, 4.01)	2395/5868	1083/5546	67.09
Overall (I-squared = 80.2%, p = 0.000)	2.58 (2.11, 3.17)	3165/7454	2092/8557	100.00
NOTE: Weights are from random effects analysis				
.1 1 2.5	50			

#### Figure S11 30-day and in-hospital mortality in patients with CFS 1–4 vs 5–9


Patients with CFS 4–9 have significantly higher odds of 30-day mortality (OR: 1.84; CI: 1.40–2.41) and in-hospital mortality (OR: 3.10; CI: 2.40–4.01), the overall odds ratio being 2.58 (CI: 2.11–3.17). Note that heterogeneity was significant in both subgroups. OR: odds ratio; CI: confidence interval. P>0.1 was considered significant.

#### Figure S12 — Forest plot grouped by age restriction



#### Figure S12 Mortality in patients with CFS 1–4 vs 5–9, with studies grouped by age restriction


Studies only enrolling patients older than 65 years of age have an overall odds ratio of 2.07 (CI: 1.50–2.85) for mortality in patients CFS 5–9 while studies without age restriction have an overall OR of 3.10 (CI: 2.11–3.17). Note that heterogeneity was significant in both subgroups and for the overall results as well. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.



#### Figure S13 Leave-one-out sensitivity analysis for studies reporting mortality in patients with CFS 1– 4 vs CFS 5–9

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

### Figure S14 – Funnel plot




#### Figure S14 Funnel plot for mortality in patients with CFS 1-4 vs 5-9

Based on the visual inspection of the funnel plot and the result of the Eggers' test (p=0.813) no small study effect was identified.

## Mortality in patients with CFS 1–5 vs 6–9

#### Figure S15 – Forest plot, studies grouped by country



#### Figure S15 Mortality comparing CFS 1–5 and CFS 6–9 groups, with studies grouped by country

Studies from the UK have an overall odds ratio of 2.52 (CI: 1.98–3.21) for mortality in patients with CFS 6–9 while studies outside the UK (non-UK) showed a similar subtotal OR of 2.55 (CI: 1.97–3.63). Note that heterogeneity was significant in both subgroups and for the overall results as well. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.


#### Figure S16 — Forest plot for mortality grouped by follow-up

Studies	OR (95% CI)	% Weight	CFS 6-9 event	CFS 1-5 event
30 day mortality				
Owen, R. K. et al. (2020)	0.92 (0.52, 1.61)	4.93	36/83	56/123
Davis, P. et al. (2020)	1.94 (1.13, 3.33)	5.10	56/110	39/112
Bielza, R. et al. (2021)	2.23 (1.50, 3.31)	6.44	./.	./.
Jung, C. et al. (2021)	2.37 (1.71, 3.29)	7.10	104/172	451/1150
Aliberti, M. J. R. et al. (2020)	2.45 (1.90, 3.17)	7.80	157/287	509/1543
Subtotal (I-squared = 61.6%, p = 0.034)	2.00 (1.51, 2.65)	31.37		
In-hospital mortality				
Piers, R. et al. (2021)	1.33 (0.97, 1.83)	7.22	151/405	94/305
Blomaard, L. C. et al. (2021)	1.76 (1.34, 2.30)	7.67	148/313	251/743
Aw, D. et al. (2020)	2.31 (1.68, 3.19)	7.15	183/369	88/295
Hewitt, J. et al. (2020)	2.52 (2.00, 3.16)	8.05	236/617	186/942
Ponsford, M. J. et al. (2021)	2.71 (2.14, 3.43)	7.99	247/479	233/826
Welch, C. et al. (2021)	2.76 (2.43, 3.14)	8.81	736/1837	632/3244
Andrés-Esteban, E. M. et al. (2021)	3.13 (1.39, 7.05)	3.26	19/29	85/225
Sablerolles, R. S. G. et al. (2021)	3.56 (2.85, 4.45)	8.09	182/493	274/1941
Burns GP et al. (2020)	3.67 (0.70, 19.12)	1.08	7/10	7/18
Tehrani, S. et al. (2021)	◆ 7.33 (2.91, 18.45)	2.74	26/33	37/110
Chinnadurai, R. et al. (2020)	◆ 8.13 (4.36, 15.15)	4.44	64/98	22/117
Marengoni, A. et al. (2020) -	• 14.04 (4.67, 42.20)	2.12	15/20	25/142
Subtotal (I-squared = 82.1%, p = 0.000)	2.90 (2.31, 3.65)	68.63		
.				
Overall (I-squared = 79.1%, p = 0.000)	2.55 (2.13, 3.07)	100.00		
NOTE: Weights are from random effects analysis				
	I			
.1 1 2.5	50			

#### Figure S16 30-day and in-hospital mortality in patients with CFS 1–5 vs 6–9

Patients with CFS 4–9 have significantly higher odds of 30-day mortality (OR: 2.00; CI: 1.51–2.65) and in-hospital mortality (OR: 2.90; CI: 2.31–3.65), the overall odds ratio being 2.55 (CI: 2.13–3.07). Note that heterogeneity was significant in both subgroups. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.


#### Figure S17 — Forest plot grouped by age restriction



## Figure S17 Mortality comparing CFS 1–5 and CFS 6–9 groups, with studies grouped by age restriction

Studies only enrolling patients older than 65 years of age have an overall odds ratio of 1.95 (CI: 1.46–2.60) for mortality in patients with CFS 6–9 while studies without age restriction have an overall OR of 3.04 (CI: 2.52–3.66). Note that heterogeneity was significant in both subgroups and for the overall result as well. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.


#### Figure S18 — Leave-one-out analysis



#### Figure S18 Leave-one-out sensitivity analysis for studies reporting mortality in patients with CFS 1– 5 vs CFS 6–9

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

### Figure S19 – Funnel plot




#### Figure S19 Funnel plot for mortality in patients with CFS 1–5 vs 6–9

Based on the visual inspection of the funnel plot and the result of the Eggers' test (p=0.792) no small study effect was identified.

### Weighted Mean Difference of CFS


#### Figure S20 – Forest plot, studies grouped by country



#### Figure S20 Weighted mean difference of CFS score for mortality with studies grouped by country

Non-survivors average CFS scores were significantly higher than survivors' in both the UK and the non-UK subgroup (WMD: 0.99; CI: 0.48–1.50 for non-UK and WMD: 1.45; CI: 1.03–1.88 for UK subgroup) Please note the significant heterogeneity in both subgroups and for the overall result. WMD: weighted mean difference; SD: standard deviation; CI: confidence interval. P<0.1 was considered significant.


#### Figure S21 – Forest plot for mortality grouped by follow-up



#### Figure S21 Weighted mean difference of CFS score for mortality with studies grouped by follow-up

Non-survivors average CFS scores were significantly higher than survivors' in both the 30-day and the in-hospital mortality subgroup (WMD: 1.22; CI: 0.35–2.08 for 30-day and WMD: 1.20; CI: 0.86–1.54 for in-hospital mortality subgroup) Please note the significant heterogeneity in both subgroups and for the overall result. WMD: weighted mean difference; SD: standard deviation; CI: confidence interval. P<0.1 was considered significant.

#### Figure S22 — Leave-one-out analysis



## Figure S22 Leave-one-out sensitivity analysis for studies reporting average frailty indicated by CFS in survivors and non-survivors

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

#### Figure S23 – Funnel plot





Figure S23 Funnel plot for frailty difference in survivors vs non-survivors

Based on the visual inspection of the funnel plot and the result of the Eggers' test (p=0.108) no small study effect was identified.

## Mortality in patients with MPI 1 vs 2+3 Figure S24 – Forest plot




#### Figure S24 Mortality in patients with MPI 1 vs 2 and 3

Patients with in the MPI 2 and 3 category have an overall odds ratio of 4.31 (CI: 0.91–20.49) for mortality compared to patients in the MPI 1 category. Note that heterogeneity was significant. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.

## ICU admission in patients with CFS 1–3 vs 4–9

Figure S25 – Leave-one-out analysis



## Figure S25 Leave-one-out sensitivity analysis for studies reporting ICU admission in patients with CFS 1–3 vs CFS 4–9

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

#### Figure S26 – Funnel plot





Figure S25 Funnel plot for ICU admission in patients with CFS 1–3 vs 4–9

Visual inspection raises the suspicion of small-study effect. Egger's test was not conducted due to the low number of studies.


## ICU admission in patients with CFS 1–4 vs 5–9 Figure S27 – Forest plot



#### Figure S27 ICU admission in patients with CFS 1–4 vs 5–9

COVID-19 patients with CFS 5-9 have an overall OR of 0.09 (CI: 0.04–0.22). Note significant heterogeneity. OR: odds ratio; CI: confidence interval. P<0.1 was considered significant.


#### Figure S28 – Leave-one-out analysis



## Figure S28 Leave-one-out sensitivity analysis for studies reporting ICU admission in patients with CFS 1–4 vs CFS 5–9

Each row shows the overall OR and CI with the omission of the indicated study. There is no study the omission of which would change statistical significance.

#### Figure S29 – Funnel plot



**Figure S29 Funnel plot for ICU admission in patients with CFS 1–4 vs 5–9** Visual inspection does not raise the suspicion of small-study effect. Egger's test was not conducted due to the low number of studies.

## Length of hospital stay

Summary of reported results

A se al se é a	CFS	1-3	4	5 – 9	
Andrés- Esteban	median	11	10	5	
	(IQR)	(9 – 19)	(7 – 14)	(1 – 11)	
Bavaro	CFS	1 – 3	4 – 6	7 – 9	
	median (IQR)	22 (15 – 42)	25 (14 – 37)	21 (7 – 37)	
Blomaard	CFS	1-3	4 – 5	6 - 9	
	median (IQR)	6 (3 – 11)	6 (3 – 10)	6 (3 – 10)	
Hewitt	CFS	1 – 2	3 – 4	5 - 6	7 – 9
	Crude HR (95% Cl)	1	0.87 (0.71 – 1.05)	0.61 (0.49 – 0.76)	0.56 (0.44 – 0.72)
Kundi	LOS > 10 days HFRS	<5	5–15	>15	
	Adjusted OR (95% CI)	1.00	1.152 (1.067 – 1.243)	1.317 (1.169 – 1.483)	
Osuafor	LOS > 10 days CFS	All	1-4	5 – 8	
	n / all (%)	114 / 214 (53.5)	32 / 72 (45.1)	82 / 142 (57.8)	
Ramos- Rincon	CFS LOS > 10 days	all	1-4	5 - 6	7 – 9
	n / all (%)	131 / 290 (45.2)	109 / 236 (46.2)	15 / 33 (45.5)	7 / 21 (33.3)
	HFRS LOS > 10 days	all	> 5	5 – 15	> 15
	n / all (%)	131 / 290 (45.2)	89 / 225 (39.6)	31 / 49 (63.3)	11 / 16 (68.8)

### References

- 1. Hayden JA, Côté P, Bombardier C: **Evaluation of the Quality of Prognosis Studies in Systematic Reviews**. *Annals of Internal Medicine* 2006, **144**(6):427-437.
- 2. Grooten WJA, Tseli E, Äng BO, Boersma K, Stålnacke B-M, Gerdle B, Enthoven P: **Elaborating** on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS—aspects of interrater agreement. *Diagnostic and Prognostic Research* 2019, **3**(1):5.